Abstracts Archive - Page 2392 of 2425 - ACR Meeting Abstracts

Abstract Number: 434 • 2012 ACR/ARHP Annual Meeting
IL-22 Mediated Pannus Formation in Autoimmune Arthritis Is PI3K/Akt/mTOR Dependent
Siba P. Raychaudhuri¹, Anupam Mitra¹, Ananya Datta Mitra², Christine Abria² and Smriti K. Raychaudhuri², ¹Rheumatology, VA Sacramento Medical CenterUC Davis School of Medicine, Mather, CA, ²Rheumatology, VA Sacramento Medical Center, Mather, CA
Background/Purpose: IL-22, a Th17 cytokine plays a key role in the formation of “pannus” in autoimmune arthritis such as rheumatoid arthritis (RA) and psoriatic arthritis…
Abstract Number: 435 • 2012 ACR/ARHP Annual Meeting
CIP2A Facilitates Apoptotic Resistance of Fibroblast-Like Synoviocytes in Rheumatoid Arthritis Independent of c-Myc Expression
Jaejoon Lee¹, Jiwon Hwang¹, Jinseok Kim², Joong Kyong Ahn³, Hoon-Suk Cha¹ and Eun-Mi Koh⁴, ¹Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ²Internal Medicine, Jeju National University Hospital, Jeju, South Korea, ³Department of Medicine, Kangbuk Samsung hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁴Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Seoul, South Korea
Background/Purpose: Cancerous inhibitor of protein phosphatase 2A (CIP2A) is a recently identified oncoprotein that leads to cellular proliferation in cancer cells by stabilizing c-Myc protein.…
Abstract Number: 436 • 2012 ACR/ARHP Annual Meeting
Synthetic Anti-CCP Antibody Aggravated Severity of Animal Arthritis and Captured Citrullinated Antigen in the Serum of Patients with Rheumatoid Arthritis
Youngkyun Kim¹, Su-Jin Moon², Hyoju Yi² and Ji Hyeon Ju³, ¹1Convergent Research Consortium for Immunologic Disease, The Catholic University of Korea, Seoul, South Korea, ²Rheumatology, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ³Rheumatology, College of Medicine, The Catholic University of Korea & Stanford University, Seoul & Palo Alto, CA
Background/Purpose: Auto-antibodies against citrullinated protein antigens (ACPA) have shown their relevance for the prognosis and diagnosis of rheumatoid arthritis (RA), and have been implicated in…
Abstract Number: 437 • 2012 ACR/ARHP Annual Meeting
SIRT6 Regulates Cigarette Smoke Induced MMP1 Expression in Rheumatoid Arthritis Synovial Fibroblasts
Anna Engler¹, Renate E. Gay², Beat A. Michel², Steffen Gay² and Caroline Ospelt², ¹Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP), Zurich, Switzerland
Background/Purpose: Cigarette smoking is the best-known environmental risk factor for the development of rheumatoid arthritis (RA). However, the molecular mechanisms involved in the association of…
Abstract Number: 438 • 2012 ACR/ARHP Annual Meeting
Methyl Supplementation of Rheumatoid Arthritis Synovial Fibroblasts Regulates the Expression of Transcription Factors and Matrix Metalloproteinases
Edvardas Bagdonas¹, Emmanuel Karouzakis², Astrid Jungel², Caroline Ospelt¹, Renate E. Gay¹, Steffen Gay¹, Beat A. Michel¹ and Michel Neidhart¹, ¹Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP), Zurich, Switzerland
Background/Purpose: Previously we reported that methyl supplementation can reverse the global hypomethylation of rheumatoid arthritis synovial fibroblasts (RASF) and attenuate their aggressive behaviour. Now we…
Abstract Number: 439 • 2012 ACR/ARHP Annual Meeting
Interaction of Antibodies Against Citrullinated Peptides with HLA Shared Epitope, PTPN22 1858T Variant, and Smoking in Individuals Prior to and After the Development of Rheumatoid Arthritis
Heidi Kokkonen¹, Mikael Brink², Monika Hansson³, Linda Mathsson⁴, Ewa Lassen⁵, Per Johan Jakobsson⁶, Rikard Holmdahl⁷, Johan Rönnelid⁴, Lars Klareskog⁸ and Solbritt M. Rantapaa-Dahlqvist⁹, ¹Rheumatology, Umeå University, Umea, Sweden, ²Umea University, Umea, Sweden, ³Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden, ⁵Transfusional Medicin, Umeå University, Umeå, Sweden, ⁶Rheumatology unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁷Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden, ⁸Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden, ⁹Rheumatology, Institution of Public health and clinical medicine/ Rheumatology, University of Umeå, Umeå, Sweden, Umea, Sweden
Background/Purpose: The presence of antibodies against cyclic citrullinated peptides (ACPA) has been demonstrated to precede the development of rheumatoid arthritis (RA) by several years. The…
Abstract Number: 440 • 2012 ACR/ARHP Annual Meeting
Effects of Fetal Microchimerisms On Disease Onset and Severity in Women with Rheumatoid Arthritis and Systemic Lupus Erythematosus
Marianne Kekow¹, Sara Fill Malfertheiner², Maria Barleben¹, Susanne Drynda³, Joern Kekow³ and Thomas Brune¹, ¹Univ of Magdeburg, Children's Hospital, Magdeburg, Germany, ²Univ of Magdeburg, Department of Obstetrics and Gynecology, Magdeburg, Germany, ³Clinic of Rheumatology, Univ of Magdeburg, Vogelsang-Gommern, Germany
Background/Purpose: The major source of naturally acquired microchimerisms (MC) is the transplacental traffic of fetal cells between a mother and the fetus during pregnancy. Fetal…
Abstract Number: 441 • 2012 ACR/ARHP Annual Meeting
Performance of Anti-Cyclic Citrullinated Peptide Assays Differs in Healthy Subjects At Elevated Risk for Future Rheumatoid Arthritis and Subjects with Established Disease
M. Kristen Demoruelle¹, Mark Parish², Lezlie A. Derber³, Michael H. Weisman⁴, William R. Gilliland⁵, Jess Edison⁶, James R. O'Dell⁷, Ted R. Mikuls⁸, Richard M. Keating⁹, Peter K. Gregersen¹⁰, Jane H. Buckner¹¹, Jill M. Norris¹², V. Michael Holers¹³ and Kevin D. Deane¹, ¹Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ²Rheumatology, University of Colorado Anschutz Medical Campus, Aurora, CO, ³University of Colorado School of Medicine, Division of Rheumatology, Aurora, CO, ⁴Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁵Walter Reed National Military Medical Center, Bethesda, MD, ⁶Department of Rheumatology, Walter Reed National Military Medical Center, Bethesda, MD, ⁷Dept of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ⁸Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ⁹Rheumatology Section, The University of Chicago, Chicago, IL, ¹⁰Genomics and Human Genetics, North Shore University Hospital Research Center, Manhasset, NY, ¹¹Benaroya Research Institute at Virginia Mason, Seattle, WA, ¹²Epidemiology, Colorado School of Public Health, Aurora, CO, ¹³Rheumatology Division, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: The 2010 ACR/EULAR RA criteria include autoantibodies to cyclic citrullinated peptides (CCP) that are highly specific for RA in the setting of inflammatory arthritis…
Abstract Number: 442 • 2012 ACR/ARHP Annual Meeting
Joint Effects of Known Genetic Markers of Rheumatoid Arthritis Risk and 25-Hydroxyvitamin D On Rheumatoid Arthritis Risk
Linda T. Hiraki¹, Chia-Yen Chen², Jing Cui³, Susan Malspeis⁴, Karen H. Costenbader⁴ and Elizabeth W. Karlson⁵, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard School of Public Health, Boston, MA, ²Epidemiology, Harvard School of Public Health, Boston, MA, ³Rheumatology, Brigham and Women's Hospital, Boston, MA, ⁴Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) is a complex disease with both genetic and environmental risk factors. A number of susceptibility genes have been identified. Past studies…
Abstract Number: 443 • 2012 ACR/ARHP Annual Meeting
Secreted Frizzled-Related Protein 5 Exerts the Anti-Inflammatory Role in Rheumatoid Arthritis Via Down-Regulation of c-Jun N-Terminal Kinase
Yong-Jin Kwon¹, Tae-Yeon Kim², Sang-Won Lee³, Yong-Beom Park³, Soo Kon Lee⁴ and Min-Chan Park¹, ¹Department of Internal Medicine, Yonse University College of Medicine, Seoul, South Korea, ²Dept. of Internal Medicine, Yonse University College of Medicine, Seoul, South Korea, ³Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea, ⁴Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea
Background/Purpose: Secreted frizzled-related protein 5 (Sfrp5) is a novel adipokine that has beneficial effects on metabolic dysfunction by controlling inflammatory cells within adipose tissue. Sfrp5…
Abstract Number: 444 • 2012 ACR/ARHP Annual Meeting
Tocilizumab Improves Bone Mineral Density Compared with Abatacept in Patients with TNF Blockers-Resistant Active Rheumatoid Arthritis. an Open Label Randomized Controlled Trial
Kensuke Kume¹, Kanzo Amano¹, Susumu Yamada¹, Kazuhiko Hatta², Kuniki Amano³, Noriko Kuwaba⁴ and Hiroyuki Ohta⁵, ¹Rheumatology, Hiroshima Clinic, Hiroshima, Japan, ²Rheumatology, Hatta Clinic, Kure, Japan, ³Rheumatology, Sky Clinic, Hiroshima, Japan, ⁴Medical Research, Sanki Clinical Link, Hiroshima, Japan, ⁵Medical Research, hiroshima clinic, Hiroshima, Japan
Background/Purpose: To compare the effect of tocilizumab(TCZ) plus methotrexate (MTX), with the effect of abatacept(ABT) plus MTX on bone mineral density(BMD) in TNF blockers resistant…
Abstract Number: 445 • 2012 ACR/ARHP Annual Meeting
Combination of Intra-Articular Steroid Injection and Infliximab More Effective Than Infliximab in Rapid Radiographic Progression Patients with Rheumatoid Arthritis: A Randomized, Open Label, x Ray Reader Blinded Study
Kensuke Kume¹, Kanzo Amano¹, Susumu Yamada¹, Kazuhiko Hatta², Kuniki Amano³, Hiroyuki Ohta⁴ and Noriko Kuwaba⁵, ¹Rheumatology, Hiroshima Clinic, Hiroshima, Japan, ²Rheumatology, Hatta Clinic, Kure, Japan, ³Rheumatology, Sky Clinic, Hiroshima, Japan, ⁴Medical Research, hiroshima clinic, Hiroshima, Japan, ⁵Medical Research, Sanki Clinical Link, Hiroshima, Japan
Background/Purpose: Treatment of rheumatoid arthritis (RA) should aim at full remission. However, recent publications described rapid radiographic progression (RRP) existed despite initial biologics and methotrexate…
Abstract Number: 446 • 2012 ACR/ARHP Annual Meeting
Clinical Remission and Rate of Relapse After Tocilizumab Withdrawal in Rheumatoid Arthritis Patients
Cesar Vargas-Serafin¹, Luis Aguilar-Lozano¹, Jorge Padilla-Ibarra¹, Carlos Sandoval-Castro¹, Jose Dionisio Castillo-Ortiz¹, Jorge Morales-Torres², Claudia Hernandez² and Cesar Ramos-Remus¹, ¹Unidad de Investigacion en Enfermedades Cronico-Degenerativas, Guadalajara, Mexico, ²Rheumatology, Hospital Aranda de la Parra, Leon, Mexico
Background/Purpose: Although there is much discussion regarding when to initiate a biological agent in rheumatoid arthritis (RA) patients, data on when to stop these agents…
Abstract Number: 447 • 2012 ACR/ARHP Annual Meeting
Long-Term Safety and Efficacy of Tabalumab, an Anti-B-Cell Activating Factor Monoclonal Antibody, in Patients with Rheumatoid Arthritis: A 52-Week, Open-Label Extension Study
Maria W. Greenwald¹, Leszek Szczepanski², Alastair C. Kennedy³, Chin H. Lee⁴, Emery Polasek⁵, Melissa Veenhuizen⁴, Rebecca Jones-Taha⁶ and Pierre-Yves Berclaz⁵, ¹Desert Medical Advances, Palm Desert, CA, ²Wydz. Fizjoterapii, Wyzsza Skola Spoleczno-Przyrodnicza, Poland, ³Alastair C. Kennedy, MD, Vero Beach, FL, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Eli Lilly & Company, Indianapolis, IN, ⁶PharmaNet/i3, Blue Bell, PA
Background/Purpose: Tabalumab, a monoclonal antibody that neutralizes membrane-bound and soluble B cell activating factor (BAFF), has been shown to reduce rheumatoid arthritis (RA) signs and…
Abstract Number: 448 • 2012 ACR/ARHP Annual Meeting
Sustained and Cumulated Response Over Time in Rheumatoid Arthritis Patients Treated with Rituximab After Initial Failure of Anti Tumor Necrosis Factor Agents
Ioan Ancuta¹, Catalin Codreanu², Ruxandra Ionescu³, Magda Parvu⁴ and Mihai Bojinca⁵, ¹Internal Medicine, Cantacuzino Hospital, Bucharest, Romania, ²Rheumatology, “Dr. I. Stoia” Center for Rheumatic Diseases, Bucharest, Romania, ³Clinic Hospital "Sf. Maria", Bucharest, Romania, ⁴Internal Medicine, “N.Gh. Lupu” Clinical Hospital, Bucharest, Romania, ⁵Internal Medicine, “Dr. I. Cantacuzino” Hospital, Bucharest, Romania
Background/Purpose: Although anti-TNF therapies moved forward the treatment of rheumatoid arthritis (RA), failure of the first anti-TNF medication is not uncommon. Many times modifying dosage/frequency…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].